Pharmacological and/or genetic inhibition of SIRT2 improves disease pathology in models of AD (Silva et al., 2016), HD (Luthi‐Carter et al., 2010), PD, and cerebral ischemia, but not in models of the motor neuron disease amyotrophic lateral sclerosis (ALS) (Chen et al., 2015b). Here, SIRT2 is linked to Huntington disease.